Lead Product(s) : CAS 138564-60-0
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Emeriti Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The first candidate in the VP03 program, new AT2R agonist C106, shows high selectivity for AT2R and good activity in reducing TGFb in human tissue with patent protection to 2041, is ready to enter a phase 1 trial.
Product Name : C106
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 23, 2022
Lead Product(s) : CAS 138564-60-0
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Emeriti Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RES030-085
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $0.3 million
Deal Type : Agreement
Iconovo and Respiratorius Sign Agreement for Development of Inhalation Product to Treat COPD
Details : The agreement focuses on the development of an inhalation formulation as well as an inhalation product for phase I studies for Respiratorius drug candidate RES030-085 within the RESP9000 project for the treatment of COPD and severe asthma.
Product Name : RES030-085
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 20, 2021
Lead Product(s) : RES030-085
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $0.3 million
Deal Type : Agreement
Lead Product(s) : VP01
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Administration of clinically relevant oral doses of VP01 in the so called Sugen-Hypoxia-induced pulmonary hypertension model in rats caused a significant and therapeutically meaningful reduction in pulmonary arterial pressure without affecting the system...
Product Name : VP01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2020
Lead Product(s) : VP01
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable